April - June 2024 | Office of the Vermont Attorney General

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Apotex%20Corp%20-%20Eribulin%20Mesylate%20Injection%20-%20VT%203%20Day%20Reporting_5.8.24.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Apotex%20Corp%20-%20Pirfenidone%20Tablet%20-%20VT%203%20Day%20reporting_04092024.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Apotex%20VT%2030%20Day%20Reporting_Cetrorelix%20Acetate%20for%20Injection_6.11.2024.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Apotex%20VT%2030%20Day%20Reporting_Pirfenidone%20Tablets_%2005032024.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Boehringer%20Ingelheim%20Pharmaceuticals%2C%20Inc_%20VT%2030%20Day%20Reporting_Spevigo.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Boehringer_%20VT%2030%20Day%20Reporting_Cyltezo%20Adalimumab%20HC.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Celltrion%20USA_Adalimumab-aaty_VT_%203%20Day%2005.03.24.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Celltrion%20USA_Adalimumab-aaty_VT_%2030%20Day%2005.28.24.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Celltrion%20USA_Zymfentra%20120mg_VT%2030%20Day%20Reporting_04.11.2024.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Chartwell%20-%20VT%20New%20Drug%20Notice%20%20Report%20-%204.5.24.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Drug%20Price%20Transparency%20-%203%20Day%20Notice%20-%20VT%20Calcitonin.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Drug%20Price%20Transparency%20-%2030%20Day%20Notice%20-%20VT%20Lacosamide.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/GC_Biopharma_Alyglo_VT_30%20Day_04.19.24.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Invivyd%20VT%203-day%20Notice.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Invivyd%20VT%2030-day%20Report.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Madrigal%20VT%20New%20Drug%20Notice.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/New%20Prescription%20Drug%20Notice%206.11.24%20to%20the%20state%20of%20VT%20(Ss%204637).docx.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/New%20Product%20report%20DOCIVYX.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/NH%20New%20Drug%20Notice.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Notice%20of%20a%20New%20Prescription%20Drug%20Pursuant%20to%2018%20V.S.A%20%C2%A7%204637(b)-BEQVEZ.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Notice%20of%20a%20New%20Prescription%20Drug%20Pursuant%20to%2018%20V.S.A%20%C2%A7%204637(b)-TALZENNA%20soft%20gel%20capsules.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Notice%20of%20a%20New%20Prescription%20Drug%20Pursuant%20to%2018%20V.S.A%20%C2%A7%204637(c)%20-%20BEQVEZ.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Notice%20of%20a%20New%20Prescription%20Drug%20Pursuant%20to%2018%20V.S.A%20%C2%A7%204637(c)%20-%20Talzenna%20soft%20gels.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Pangea%20VT%20Filing%20-%20Selenious%20Acid%20400%2006242024.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/SKLSI%20XCopri%2025%20mg%20New%20Drug%20Notice%20VT%205.15.24.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Solubiomix%20-%20Vermont%20New%20Drug%20Notice.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/SpringWorks%20VT%20New%20Drug%20Notice.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Sun%20Vermont%20New%20Drug%20Notice%20and%20Report%20Mixed%20Amphetamines.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Taro%20Vermont%20New%20Drug%20Notice%20and%20Report%20Deferiprone%201000mg%2050ct.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/TOFIDENCE%20-%20VT%203-Day%20New%20Drug%20Notice.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/TOFIDENCE%20-%20VT%2030-Day%20New%20Drug%20Report.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Tyenne%20VT%2030-day%20Report.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Vermont%20-%20Biocon%20-%20Everolimus%20Tablets%202.5mg%20Drug%20Price%20Reporting_04.17.2024.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Vermont%203_Day%20Notice%20WINREVAIR.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Vermont%20Report_Adilimumab_Quallent.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Vermont%20Report_Lanreotide.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Vermont%20Report_Tetracycline.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Vermont%20SDPT%20Initial%20Drug%20Notification%20-%20Jylamvo.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Vermont%20WAC%20Reporting%20-%20Indomethacin%20Suppository%2050mg%20N%2B%2004.26.2024.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Vermont%20WAC%20Reporting%20-%20MIrabegron%2025mg%20%26%2050mg%20Tabs%2004.22.2024.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/Vermont_NEWPRODUCT_TORPENZ_3day_2024.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20-%203%20Day%20Reporting%20-%20Apotex%20Corp%20-%20Cetrorelix%20Acetate%20for%20Injection.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20-%20Adalimumab%2020mg%20-%2030%20Day%20Reporting.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20-%20Apotex%2030%20Day%20Reporting_Eribulin%20Mesylate%20Injection_6.3.2024.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20-%20Novugen%20Pazopanib%20Tablets.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%203-day%20Cyltezo%20Adalimumab.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%203-day%20Spevgio%20GPP.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%2030%20Day%20File%20-%20Opsvsni.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20Act%20193%20New%20Drug%20Report_Lenmeldy_5.22.2024.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20Act%20193%20New%20Drug%20Report_Libervant_5.31.2024.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20Letter%20to%20Office%20of%20Attorney%20General_New%20Drug%20Report%20Email%20-%20Foscamet.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20New%20Drug%20Initial%20Notice%20Report%20-%20INGREZZA%20SPRINKLE%20capsules.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20New%20Drug%20Notice.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20New%20Drug%20Notice_Libervant_5.16.2024.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20New%20Drug%20Pricing%20Report%20-%20Simlandi.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20New%20Drug%20Pricing%20Report%20-Austedo%20XR%20May%202024.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20New%20Drug%20Pricing%20Report%20-Simlandi.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20New%20Drug%20Report%20-%2030-Day%20Report_Blister%20Packs.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20New%20Drug%20Report%20-%20INGREZZA%20SPRINKLE%2040mg_60mg_80mg%20capsules.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20New%20Drug%20Report%20Cordavis%20Humira%20(1).pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20New%20Drug%20Report%20pdf.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20New%20Drug%20Report.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20New%20Drug%20Reporting%20-%20Filsuvez%2010122.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20Posaconazole%2030%20Day%20Mylan%20Institutional.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20Submission%20-%2020240517.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT%20Xcopri%2030%20Day%2005.28.2020.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT_30-Day-Reporting%20Fasenra%20Ped.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT_30-Day-Reporting%20Voydeya.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT_Act_193_New_Drug_Notice_4.19.24.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT_Imdelltra_30-DAY_Final.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT_New%20Prescription%20Drug%20Notice%20-%20TYVASO%20DPI%2004-01-2024.docx.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT_New%20Prescription%20Drug%20Notice-%20ojemda%20(tovorafenib).pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT_New%20Prescription%20Drug%20Report%20-ojemda.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT_New_Prescription_Drug_Report__Final.docx.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q2/VT_Product_Notification_3Day%20Fasenra%20Ped.pdf